February 16, 2023
MOONSONG Phase II trial
The MOONSONG Phase II trial tested AT-527, a potential oral COVID-19 antiviral, across multiple countries during the pandemic. NWEH’s FARSITE platform enabled rapid identification and recruitment of eligible patients within a crucial five-day testing window, while its on-site team supported GP practices with patient contact, sample collection, and data entry. Despite the primary endpoint not being met overall, results showed a reduction in viral load in high-risk patients at higher doses, informing the design of the upcoming Phase III MORNINGSKY trial. The study demonstrated how FARSITE can accelerate recruitment and streamline real-world trials, even under pandemic constraints.
